Drugs in ATC Class A10

Up to Top Level ATC Classes

Up to A - Alimentary tract and metabolism

Subclasses in ATC: A10 - DRUGS USED IN DIABETES

A10B - BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS

A10 Market Analysis and Financial Projection

The global market for ATC Class A10 (Drugs Used in Diabetes) is undergoing transformative growth driven by rising disease prevalence, innovations in drug development, and complex patent strategies that shape competitive dynamics. Here's a comprehensive analysis:

---

Market Dynamics

Growth Drivers

• Diabetes Epidemic: With 1 in 10 adults globally affected by diabetes, rising obesity rates and sedentary lifestyles are accelerating demand. The type 2 diabetes market alone is projected to grow from $43.02B in 2025 to $73.31B by 2032 (CAGR 7.9%)[4][11].
• Novel Drug Adoption: SGLT2 inhibitors (56.67% share), DPP-4 inhibitors (30.83%), and GLP-1 receptor agonists (10.68%) now account for 11.17% of total A10 drug usage[1][8]. Ozempic (semaglutide) dominates sales, fueled by off-label weight-loss use and celebrity endorsements[15].

• Regional Trends:	Region	Key Factors
  U.S.	Strong R&D pipeline with 100+ antihyperglycemic agents in trials[12][16]
  Europe	High financial burden from diabetes complications drives demand[12]
  Asia-Pacific	Rising obesity rates and healthcare access improvements[11]

Regulatory and Cost Challenges

• High prices for advanced therapies and 52% of insulin patents covering delivery devices hinder affordability[7][13]. Policy reforms are urged to expedite generic entry[7].

---

Patent Landscape

Key Strategies by Innovators

1. Evergreening Tactics:
   • Novo Nordisk’s Ozempic relies on compound patents (e.g., US ‘343 patent expiring 2031) and method-of-use patents (e.g., ‘462 patent expiring 2033)[2].
   • 86% of insulin products have ≥1 post-approval patent, extending exclusivity by 10+ years[7].
2. Delivery System Focus:
   • Continuous glucose monitoring (CGM) saw 6,181 patents filed globally by 2022, dominated by U.S. applicants (58%)[9]. Abbott’s FreeStyle Libre and Dexcom lead in CGM innovation[13].
3. Oral Formulation Patents:
   • Rybelsus (oral semaglutide) patents extend to 2039, while Wegovy’s weight-loss patents may delay competition until ~2040[2].

Generic Entry Outlook

• Ozempic generics are expected post-2032, pending litigation outcomes[2][15].
• Insulin biosimilars face hurdles due to device patents, but 2469/8095 BGM/CGM patents expired by 2021[13].

---

Competitive Landscape

Dominant Players

• Novo Nordisk, Eli Lilly, and Sanofi collectively hold over 50% market share[11].
• Top-Selling A10 Drugs (2024):
  1. Ozempic ($14B annual sales)[15]
  2. Jardiance (empagliflozin)
  3. Trulicity (dulaglutide)[15]

Emerging Opportunities

• GLP-1/GIP dual agonists: Tirzepatide (Mounjaro) shows superior efficacy[6][11].
• Non-insulin oral therapies: Dorzagliatin and imeglimin target亚洲 markets with high unmet needs[6][11].

---

Future Outlook

• Market Expansion: Global antidiabetics sales will reach $263B by 2033, led by SGLT2 inhibitors and GLP-1RAs[16].
• Tech Integration: AI-driven glucose monitoring and “smart insulin” patches are under development[9].
• Policy Shifts: Advocacy for faster generic approvals and device patent reforms could reduce costs[7][13].

---

"The advancement of CGM technologies represents the next frontier in diabetes care, merging pharmacology with digital health." [9][13]

In summary, the A10 drug market is poised for sustained growth,但 challenges in pricing, patent strategies, and equitable access will shape its trajectory. Innovations in drug-device combinations and targeted therapies will remain critical to addressing the global diabetes burden.

References

1. https://pmc.ncbi.nlm.nih.gov/articles/PMC10988802/
2. https://www.markmanadvisors.com/blog/2025/2/7/what-is-the-patent-landscape-for-novo-nordisks-semaglutide-products-ozempic-wegovy-and-rybelsus
3. https://patents.google.com/patent/US6274549B1/en
4. https://www.coherentmarketinsights.com/industry-reports/type-2-diabetes-market
5. https://www.aeaweb.org/doi/10.1257/aeri.20210063.appx
6. https://en.wikipedia.org/wiki/ATC_code_A10
7. https://journals.plos.org/plosmedicine/article?id=10.1371%2Fjournal.pmed.1004309
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC10358769/
9. https://pmc.ncbi.nlm.nih.gov/articles/PMC10445130/
10. https://simplywall.st/stocks/us/software/nyse-aten/a10-networks
11. https://www.fortunebusinessinsights.com/industry-reports/diabetes-drugs-market-100570
12. https://www.grandviewresearch.com/industry-analysis/antidiabetics-market
13. https://pmc.ncbi.nlm.nih.gov/articles/PMC11688697/
14. https://www.iqvia.com/-/media/iqvia/pdfs/belgium/sales-trends/2020/may-belgian-reg-med-best.pdf
15. https://xtalks.com/what-are-the-top-10-diabetes-medications-a-look-at-recent-sales-trends-3984/
16. https://www.biospace.com/antidiabetics-market-size-to-reach-usd-263-12-billion-by-2033